Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

MYC-Alarmin Axis As a Novel Oncogenic Driver in a Subgroup of Triple Negative Myeloproliferative Neoplasms

Blood (2023) 142 (Supplement 1): 994.

https://doi.org/10.1182/blood-2023-174383

Published: 2023

Journal Articles

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2023-187092

Published: 2023

Journal Articles

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Blood (2023) 142 (Supplement 1): 628.

https://doi.org/10.1182/blood-2023-179141

Published: 2023

Journal Articles

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Andrew T. Kuykendall, Kristen Marie Pettit, Abhay Singh, Tania Jain, David A Sallman, Qianxing Mo, Quan Lovette, Ling Zhang, Onyee Chan, Alison R. Walker, Zhuoer Xie, Jeffrey Lancet, Maria Balasis, Seongseok Yun, Eric Padron, Rami S. Komrokji

Blood (2023) 142 (Supplement 1): 73.

https://doi.org/10.1182/blood-2023-182879

Published: 2023

Journal Articles

Improved Overall Survival Among Luspatercept Responders and Predictors of Response

Blood (2023) 142 (Supplement 1): 1871.

https://doi.org/10.1182/blood-2023-186279

Published: 2023

Journal Articles

Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool

Andrew Srisuwananukorn, Giuseppe Gaetano Loscocco, Andrew T. Kuykendall, James M Dolezal, Raffaella Santi, Ling Zhang, Avani M Singh, Paola Guglielmelli, Alessandro Maria Vannucchi, Douglas Tremblay, Alexander T Pearson, Mohamed E. Salama, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 901.

https://doi.org/10.1182/blood-2023-173877

Published: 2023

Journal Articles

Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax: A Real-World Experience in Pharmacovigilance

Mary Burke, David A Sallman, Ariel Denson, Rebecca Jean Nelson, Onyee Chan, Alison R. Walker, Eric Padron, Zhuoer Xie, Rami S. Komrokji, Jeffrey Lancet, Andrew T. Kuykendall, Katherine Tobon, Akriti Gupta Jain, Chen Wang, Najla H Al Ali

Blood (2023) 142 (Supplement 1): 2899.

https://doi.org/10.1182/blood-2023-187206

Published: 2023

Journal Articles

Durability of Hematocrit Control in Polycythemia Vera with the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results from the Revive Study

Ellen K. Ritchie, Kristen Marie Pettit, Andrew T. Kuykendall, Marina Kremyanskaya, Naveen Pemmaraju, Sarita Khanna, Arturo Molina, Suneel Gupta

Blood (2023) 142 (Supplement 1): 745.

https://doi.org/10.1182/blood-2023-178253

Published: 2023

Journal Articles

SHP2 Inhibition Enhances JAK2 Inhibitor Therapy in Preclinical Models of Myeloproliferative Neoplasms

Garima Pandey, Lucia Mazzacurati, Nathan P. Horvat, Tegan Rowsell, Narmin E. Amin, Guolin Zhang, Afua Adutwumwa Akuffo, Christelle M. Colin-Leitzinger, Eric B. Haura, Andrew T. Kuykendall, PK Epling-Burnette, Gary W. Reuther

Blood (2023) 142 (Supplement 1): 4530.

https://doi.org/10.1182/blood-2023-189657

Published: 2023

Journal Articles

Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab with Darbepoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)

David A Sallman, Anthony M Hunter, Zhuoer Xie, Amy McLemore, Andrew T. Kuykendall, Lisa Ann Nardelli, Onyee Chan, Eric Padron, Jeffrey Lancet, Rami S. Komrokji

Blood (2023) 142 (Supplement 1): 4620.

https://doi.org/10.1182/blood-2023-189226

Published: 2023

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Andrew T. Kuykendall, Somedeb Ball, Jason Gotlib, Cecilia Y. Arana Yi, Tsewang Tashi, Raajit K. Rampal, Daniel J. DeAngelo, Virginia O. Volpe, Kristen Marie Pettit, Rami S. Komrokji, Eric Padron

Blood (2023) 142 (Supplement 1): 6441.

https://doi.org/10.1182/blood-2023-184652

Published: 2023

Journal Articles

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis

Douglas Tremblay, Zaker I. Schwabkey, Yosef Joseph Rene Amel Riazat-Kesh, Grace Van Hyfte, Najla H Al Ali, Julian Waksal, Andrew Srisuwananukorn, Rami S. Komrokji, John Mascarenhas, Andrew T. Kuykendall

Blood (2023) 142 (Supplement 1): 1830.

https://doi.org/10.1182/blood-2023-179937

Published: 2023

Journal Articles

Outcomes in Patients with Acute Myeloid Leukemia Treated with CLAG (cladribine, cytarabine, filgrastim) and/or Mitoxantrone with Venetoclax

Onyee Chan, Luis E. Aguirre, Mary Burke, Najla H Al Ali, Zhuoer Xie, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Jeffrey Lancet, Rami S. Komrokji, David A Sallman

Blood (2023) 142 (Supplement 1): 5935.

https://doi.org/10.1182/blood-2023-173637

Published: 2023

Journal Articles

Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) Is Associated with Better Overall Survival

Rami S. Komrokji, Muhammad Ammad-ud-din, Najla H Al Ali, Zhuoer Xie, Onyee Chan, Andrew T. Kuykendall, Seongseok Yun, Alison R. Walker, Jeffrey Lancet, Eric Padron, David A Sallman

Blood (2023) 142 (Supplement 1): 1867.

https://doi.org/10.1182/blood-2023-186843

Published: 2023

Journal Articles

Retrospective Real-World Analysis of Baseline Characteristics and Posttreatment Hematologic Outcomes in Patients with Myelofibrosis Receiving Ruxolitinib

Andrew T. Kuykendall, Mirko Fillbrunn, Tom Liu, Adina Zhang, Ryan Simpson, Kelesitse Phiri, Gautam Sajeev, James Signorovitch

Blood (2023) 142 (Supplement 1): 6399.

https://doi.org/10.1182/blood-2023-181137

Published: 2023

Journal Articles

Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia Vera

Andrew T. Kuykendall, Abdulraheem Yacoub, Nancy Reaven, Susan Funk, Pedro Oyuela, Frank Valone, Phil Dinh, Lucy Bellamy, Nikita Modi, Arturo Molina, Suneel Gupta

Blood (2023) 142 (Supplement 1): 137.

https://doi.org/10.1182/blood-2023-180309

Published: 2023

Journal Articles

Aplastic Anemia: Insight from a Single Center Experience

Parth C. Patel, Najla H Al Ali, Onyee Chan, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Kendra Sweet, Alison R. Walker, Jeffrey Lancet, David A Sallman, Michael V. Jaglal, Rami S. Komrokji

Blood (2023) 142 (Supplement 1): 5649.

https://doi.org/10.1182/blood-2023-178952

Published: 2023

Journal Articles

Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production

Blood (2021) 138 (Supplement 1): 142.

https://doi.org/10.1182/blood-2021-148995

Published: 2021

NARROW

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

MYC-Alarmin Axis As a Novel Oncogenic Driver in a Subgroup of Triple Negative Myeloproliferative Neoplasms

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Improved Overall Survival Among Luspatercept Responders and Predictors of Response

Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool

Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax: A Real-World Experience in Pharmacovigilance

Durability of Hematocrit Control in Polycythemia Vera with the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results from the Revive Study

SHP2 Inhibition Enhances JAK2 Inhibitor Therapy in Preclinical Models of Myeloproliferative Neoplasms

Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab with Darbepoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis

Outcomes in Patients with Acute Myeloid Leukemia Treated with CLAG (cladribine, cytarabine, filgrastim) and/or Mitoxantrone with Venetoclax

Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) Is Associated with Better Overall Survival

Retrospective Real-World Analysis of Baseline Characteristics and Posttreatment Hematologic Outcomes in Patients with Myelofibrosis Receiving Ruxolitinib

Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia Vera

Aplastic Anemia: Insight from a Single Center Experience

Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only